
Frequency of Bcr-Abl Fusion Oncogene Splice Variants Associated with Chronic Myeloid Leukemia (CML)
Copyright © 2011 SciRes. JCT
180
[12] P. Chomczynski, “A Reagent for the Single-Step Simul-
taneous Isolation of RNA, DNA and Proteins from Cell
and Tissue Samples,” Biotechniques, Vol. 15, No. 3, 1993,
pp. 532-537.
[13] J. A. Glasel, “Validity of Nucleic Acid Purities Monitored
by A260/A280 Absorbance Ratios,” Biotechniques, Vol.
18, No. 1, 1995, pp. 62-63.
[14] J. Sambrook and W. D. Russel, “Molecular Cloning,” A
Laboratory Manual, Cold Spring Harbor Laboratory
Press, New York, 2001.
[15] J. J. Van-Dongen, E. A. Macintyre, J. A. Gabert, E. De-
labesse, V. Rossi, G. Saglio and E. Gottardi, “Standard-
ized RT-PCR Analysis of Fusion Genes Transcripts from
Chromosome Aberrations in Acute Leukemia for Detec-
tion of Minimal Residual Disease,” Report of the BIO-
MED-I Concerted Action: Investigation of Minimal Re-
sidual Disease in Acute Leukemia, Leukemia, Vol. 13, No.
12, 1999, pp. 1901-1928.
[16] J. P. Radich, G. Gehly, T. Gooley, E. Bryant, R. A. Clift,
S. Collins, S. Edmands, J. Kirk, A. Lee and P. Kessler,
“Polymerase Chain Reaction Detection of the BCR-ABL
Fusion Transcript After Allogeneic Marrow Transplan-
tation for Chronic Myeloid Leukemia: Results and Impli-
cations in 346 Patients,” Blood, Vol. 85, No. 9, 1995, pp.
2632-2638.
[17] J. Q. Guo, H. Lin, H. Kantarjian, M. Talpaz, R. Champlin,
M. Andreeff, A. Glassman and R. B. Arlinghaus, “Com-
parison of Competitive-Nested PCR and Real-Time PCR
in Detecting BCR-ABL Fusion Transcripts in Chronic
Myeloid Leukemia Patients,” Leukemia, Vol. 16, No. 12,
2002, pp. 2447-2453. doi:10.1038/sj.leu.2402730
[18] S. Menif, S. Zarrouki, R. Jeddi, N. ben Alaya, Z. B. Ali,
H. B. Abid, S. Hdeiji, M. Elloumi, A. Khlif, B. Meddeb
and K. Dellagi, “A Quantitative Detection of Bcr-Abl
Transcripts in Chronic Myeloid Leukemia,” Pathologie
Biologie, Vol. 57, No, 5, 2009, pp. 388-391.
doi:10.1016/j.patbio.2007.12.010
[19] Z. Iqbal and A. Tanveer, “High Incidence of Bcr-Abl
Fusion Oncogene in Pakistani Childhood Acute Lymp-
hoid Leukaemia (ALL) Patients Reflects Ethnic Differ-
ences in Molecular Genetics of ALL,” Haematologica,
Vol. 91, No. S3, 2006, p. 65.
[20] C. F. Verschraegen, H. M. Kantarjian, C. Hirsch-Ginsberg,
M. S. Lee, S. O’Brien, M. B. Rios, S. A. Stass, M. Keating
and M. Talpaz, “The Breakpoint Cluster Region Site in Pa-
tients with Philadelphia Chromosome-Positive Chronic
Myelogenous Leukemia,” Clinical, Laboratory, and Prog-
nostic Correlations, Cancer, Vol. 76, No. 6, 1995, pp.
992-997.
doi:10.1002/1097-0142(19950915)76:6<992::AID-CNCR
2820760612>3.0.CO;2-L
[21] E. Reiter, H. T. Greinix, S. Brugger, F. Keil, W. Rabitsch,
C. Mannhalter, I. Schwarzinger, P. Höcker, G. Fischer, K.
Dieckmann, W. Hinterberger, W. Linkesch, B. Schneider,
K. Lechner and P. Kalhs, “Long-Term Follow-Up after
allogeneic Stem Cell Transplantation for Chronic Mye-
logenous Leukemia,” Bone Marrow Transplant, Vol. 22,
No. S4, 1998, pp. S86-S88.
[22] H. G. Goh, J. Y. Hwang, S. H. Kim, Y. H. Lee, Y. L. Kim
and D. W. Kim, “Comprehensive Analysis of BCR-ABL
Transcript Types in Korean CML Patients Using a Newly
Developed Multiplex RT-PCR,” Translational Research,
Vol. 148, No. 1, 2006, pp. 249-256.
[23] M. Yaghmaie, S. H. Ghaffari, A. Ghavamzadeh, K. Ali-
moghaddam, M. Jahani, S. A. Mousavi, M. Irvani, B.
Bahar and I. Bibordi, “Frequency of BCR-ABL Fusion
Transcripts in Iranian Patients with Chronic Myeloid
Leukemia,” Archives of Iranian Medicine, Vol. 11, No. 3,
2008, pp. 247-251.
[24] J. A. de Lemos, C. M. de Oliveira, A. C. Scerni, A. Q.
Bentes, A. C. Beltrão, I. R. Bentes, T. C. Azevedo, L. M.
Maradei-Pereira, “Differential Molecular Response of the
Transcripts B2A2 and B3A2 to Imatinib Mesylate in
Chronic Myeloid Leukemia,” Genetics and Molecular
Research, Vol. 4, No. 4, 30 December 2005, pp. 803-811.
[25] D. Verma, H. M. Kantarjian, D. Jones, R. Luthra, G.
Borthakur, S. Verstovsek, M. B. Rios and J. Cortes,
“Chronic Myeloid Leukemia (CML) with P190 BCR-ABL:
Analysis of Characteristics, Outcomes, and Prognostic Sig-
nificance,” Blood, Vol. 114, No. 11, 10 September 2009,
pp. 2232-2235.
doi:10.1182/blood-2009-02-204693
[26] P. Sharma, L. Kumar, S. Mohanty and V. Kochupillai,
“Response to Imatinib Mesylate in Chronic Myeloid
Leukemia Patients with Variant BCR-ABL fusion Tran-
scripts,” Ann Hematology, Vol. 89, No. 3, March 2010,
pp. 241-247. doi:10.1007/s00277-009-0822-7
[27] Z. Iqbal, M. Iqbal and T. Akhter, “Frequency of
BCR-ABL Fusion Oncogene in Pakistani Childhood
Acute Lymphoid Leukemia (ALL) Patients Reflects Eth-
nic Differences in Molecular Genetics of ALL,” Journal
of Pediatric Hematology/Oncology, Vol. 29, No. 8, Au-
gust 2007, p. 585.
doi:10.1097/MPH.0b013e3180f61bcf
[28] F. X. Gruber, T. Lundán, R. Goll, A. Silye, I. Mikkola, O.
P. Rekvig, S. Knuutila, K. Remes, T. Gedde-Dahl, K.
Porkka and H. Hjorth-Hansen, “BCR-ABL Isoforms As-
sociated with Intrinsic or Acquired Resistance to Imatinib:
More Heterogeneous than just ABL Kinase Domain Point
Mutations?” Medical Oncology, 8 January 2011.
[29] Z. Iqbal, M. Iqbal, M. Akhtar, M. I. Naqvi, A. H. Tahir, T.
J. Gill, et al., “Presence of Prior-to-Treatment BCR-ABL
Mutations In CD34 + CD38-Stem Cells of Newly Diag-
nosed Chronic Phase CML Patients and Their Correlation
with Imatinib Resistance: Implications of Cancer Pharma-
cogenomics and Pre-Therapeutic Genetic Testing in Per-
sonalized Treatment of BCR-ABL+Leukemia Blood,” Vol.
116, No. 21, November 2010, p. 2278.
[30] C. M. Lucas, R. J. Harris, A. Giannoudis, A. Davies, K.
Knight, S. J. Watmough, L. Wang, R. E. Clark, “Chronic
Myeloid Leukemia Patients with the E13a2 BCR-ABL
Fusion Transcript have Inferior Responses to Imatinib
Compared to Patients with the E14a2 Transcript,”
Haematologica, Vol. 94, No. 10, October 2009, pp.
1362-1367. doi:10.3324/haematol.2009.009134